Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Myeloid Checkpoint Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for LILRB1 (CD85j / ILT2) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LILRB1 ECD-Fc Fusion / Mutant Protein (D1-D4). High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). | View LILRB1 Products |
| Gene Delivery | LILRB1 Promise-ORF / Lentivirus. Full-length ORF for stable cell lines. Cell-based assays preserve membrane conformation. | View LILRB1 Products |
| Benchmark Ab | Anti-LILRB1 Recombinant Antibody (Biosimilar). Sequence-verified positive control for binding/blockade assays. | View LILRB1 Products |
| Validator | LILRB1 siRNA Set (3 targets + control). For knockdown verification to ensure antibody specificity. | View LILRB1 Products |
| Related Target A | HLA-G. Primary biological ligand of LILRB1; essential for functional blocking assay development. | View HLA-G Products |
| Related Target B | LILRB2 (ILT4 / CD85d). Highly homologous family member; critical for off-target counter-screening. | View LILRB2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species Cyno/Mouse Evaluation | Human / Cyno / Mouse ortholog proteins with >95% purity, Sequence Verified by mass spectrometry. |
| Subfamily Off-target Binding (LILR family homology) | LILR homolog panel (LILRB1, LILRB2, LILRA) strictly Sequence Verified with high purity (>95%). |
| Ligand Competition / Blockade Assay (HLA-G) | High-purity LILRB1 ECD-Fc and HLA-G recombinant proteins for SPR/BLI and ELISA. |
| Native Conformation & Glycosylation Dependency | HEK293 expressed (Native Glycosylation) ECDs and Lentivirus for structurally accurate cell-based screening. |
| Lack of Controls | Clinical Benchmark Antibodies included as recombinant controls for assay normalization. |
| False Positives in Functional Assays | Validated siRNA included for strict specificity checks in primary macrophage/NK models. |
Live LILRB1 (CD85j) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LILRB1 (CD85j) therapeutics is intensifying, with major players shifting focus from traditional T-cell checkpoints to innate immune myeloid regulators. As first-generation monoclonal antibodies targeting the LILRB1/HLA-G axis reach the clinic, the next wave of R&D is aggressively targeting bispecific platforms to synergize myeloid cell repolarization with T-cell activation in the suppressive tumor microenvironment. Combination strategies with anti-PD-1 agents and rational patient selection based on tumor HLA-G expression are key priorities.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Antagonist) | Jounce Therapeutics, Biond Biologics, early-stage IO consortia | Solid Tumors (TAM-rich, Advanced) | Subfamily Counter Screening (Need high-purity LILR homolog panel) |
| Bispecific (e.g., PD-1 x LILRB1, HLA-G x LILRB1) | NGM Bio, Various Biotechs, Early-stage Innovators | Refractory Cancers, Immune-Evasive Tumors | Heterodimer Validation (Need distinct HEK293-expressed ECD-Fc fusions) & Ligand Blocking Assay (Need sequence-verified HLA-G and LILRB1 antigens) |
| Small Molecule / Peptide | Academic & discovery-stage programs | Refractory / Metastatic cancers | Selectivity Assay (Need LILRB2 vs. LILRB1 mutant and WT proteins) |